Field trials in Norway with SLICE®(0.2% emamectin benzoate) for the oral treatment of sea lice infestation in farmed Atlantic salmon Salmo salar

Diseases of Aquatic Organisms

,1¹  R. Simmons¹  D. J. Colquhoun¹  A. Ramstad¹  R. Nordmo¹  I. H. Sutherland¹ 

关键词: Sea lice;    Lepeophtheirus salmonis;    Caligus elongatus;    Salmo salar;    Emamectin benzoate;   

DOI  :  10.3354/dao050029

学科分类：生物科学（综合）

来源: Inter-Research

【 摘 要 】

ABSTRACT: Four commercial salmon farms on the West coast of Norway were recruited to a programme of field trials in which the efficacy of SLICE^® (0.2% emamectin benzoate; Schering-Plough Animal Health) was compared with a commercially availableproduct, EKTOBANN^® (teflubenzuron 2 g kg^-1; Skretting A/S) in treating natural sea lice Lepeophtheirus salmonis infections in Atlantic salmon Salmo salmar L. At each test site, 3 fish pens were treated with eachproduct. In total, nearly 1.2 million first-year-class fish were included in the trial, of which approximately 561000 received emamectin benzoate at a dosage of 50 µg kg^-1 body wt d^-1, while approximately 610000 receivedteflubenzuron at a dosage of 10 mg kg^-1 body wt d^-1. Medicated feed was provided at 0.5% body wt d^-1 over 7 consecutive days. Feed containing emamectin benzoate was generally well accepted by the fish and noproblems were encountered in feeding the medicated diet at the desired dose. Lice numbers were counted 2 d before and 1, 7, 14 and 21 d after commencement of treatment. While treatment with both substances rapidly reduced licenumbers, pens treated with emamectin benzoate were found to harbour significantly fewer lice 14 and 21 d post-treatment. Twenty-one days following treatment with emamectin benzoate the lice abundance was reduced on average by 94%. Limitedsampling outside the main study period indicated that emamectin benzoate protects against sea-lice infestation over longer periods.

【 授权许可】

Unknown